Wilna Vosloo

Dr. Wilna Vosloo

Australian Centre for Disease Preparedness, CSIRO-Health & Biosecurity, 5 Portarlington Road, Geelong, VIC 3220, Australia
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Preventive Veterinary Medicine
Verified
Journal Article
Closed access
CMCorissa A.J. Miller
Corissa A.J. Miller
JYJames R. Young
James R. Young
SNSonevilay Nampanya
Sonevilay Nampanya
SKSyseng Khounsy
Syseng Khounsy
NSNagendrakumar B. Singanallur
Nagendrakumar B. Singanallur
Peter Andrew WindsorPeter Andrew Windsor
Peter Andrew Windsor

11 December 2013 in Transboundary and Emerging Diseases
Verified
Journal Article
Closed access
PDF file
WVWilna Vosloo
Wilna Vosloo
JMJ. Morris
J. Morris
ADA. Davis
A. Davis
MGM. Giles
M. Giles
JWJ. Wang
J. Wang
NBNagendrakumar Singanallur Balasubramanian
Nagendrakumar Singanallur Balasubramanian

1 January 2015 in Vaccine
Verified
Journal Article
Closed access
JHJacquelyn Horsington
Jacquelyn Horsington
Zhidong ZhangZhidong Zhang
Zhidong Zhang
HBHilary Bittner
Hilary Bittner
KHKate Hole
Kate Hole
NBNagendrakumar Singanallur Balasubramanian
Nagendrakumar Singanallur Balasubramanian
WVWilna Vosloo
Wilna Vosloo

7 February 2011 in Transboundary and Emerging Diseases
Verified
Journal Article
Open access
PDF file
HEHelen E. Everett
Helen E. Everett
HCHelen Crooke
Helen Crooke
RGR. Gurrala
R. Gurrala
RDR. Dwarka
R. Dwarka
JKJ. Kim
J. Kim
TDTrevor Drew
Trevor Drew
An incursion of classical swine fever virus (CSFV) into the domestic pig population in South Africa, identified in 2005, raised the concern that infection might spread to wildlife species and be maintained in these hosts. This study sought to determine whether two wildlife Suidae species present in South Africa, the bushpig (Potamochoerus larvatus) and the common warthog (Phacochoerus africanus), could support productive CSFV infection. Both species could be infected with CSFV and transmitted infection to in-contact animals of the same species. Viral antigen and RNA genome were detected in blood/serum and animals that survived initial infection seroconverted approximately 10-14 days post-inoculation. Viral RNA remained detectable in nasal and saliva secretions for prolonged periods until monitoring ended at 42-44 days after initial challenge. These data suggest that both Suidae species could serve to spread circulating CSFV within wild populations, with implications for disease control.

Verified
Journal Article
Open access
PDF file
ACAndrea Certoma
Andrea Certoma
RLRoss A. Lunt
Ross A. Lunt
WVWilna Vosloo
Wilna Vosloo
ISIna Smith
Ina Smith
ACAxel Colling
Axel Colling
Stuart D BlacksellStuart D Blacksell
Stuart D Blacksell
Australian bat lyssavirus (ABLV) is closely related to the classical rabies virus and has been associated with three human fatalities and two equine fatalities in Australia. ABLV infection in humans causes encephalomyelitis, resulting in fatal disease, but has no effective therapy. The virus is maintained in enzootic circulation within fruit bats (Pteropid spp.) and at least one insectivorous bat variety (Saccolaimus flaviventris). Most frequently, laboratory testing is conducted on pteropodid bat brains, either following a potential human exposure through bites, scratches and other direct contacts with bats, or as opportunistic assessment of sick or dead bats. The level of medical intervention and post-exposure prophylaxis is largely determined on laboratory testing for antigen/virus as the demonstrable infection status of the in-contact bat. This study evaluates the comparative diagnostic performance of a lateral flow test, Anigen Rabies Ag detection rapid test (RDT), in pteropodid variant of ABLV-infected bat brain tissues. The RDT demonstrated 100% agreement with the reference standard fluorescent antibody test on 43 clinical samples suggesting a potential application in rapid diagnosis of pteropodid variant of ABLV infection. A weighted Kappa value of 0.95 confirmed a high level of agreement between both tests.

6 January 2022 in Viruses
Verified
Journal Article
Open access
PDF file
NBNagendrakumar Singanallur Balasubramanian
Nagendrakumar Singanallur Balasubramanian
PEPhaedra Lydia Eblé
Phaedra Lydia Eblé
ALAnna Ludi
Anna Ludi
BSBob Statham
Bob Statham
ABAbdelghani Bin-Tarif
Abdelghani Bin-Tarif
WVWilna Vosloo
Wilna Vosloo
The recent emergence and circulation of the A/ASIA/G-VII (A/G-VII) lineage of foot-and-mouth disease virus (FMDV) in the Middle East has resulted in the development of homologous vaccines to ensure susceptible animals are sufficiently protected against clinical disease. However, a second serotype A lineage called A/ASIA/Iran-05 (A/IRN/05) continues to circulate in the region and it is therefore imperative to ensure vaccine strains used will protect against both lineages. In addition, for FMDV vaccine banks that usually hold a limited number of strains, it is necessary to include strains with a broad antigenic coverage. To assess the cross protective ability of an A/G-VII emergency vaccine (formulated at 43 (95% CI 8–230) PD50/dose as determined during homologous challenge), we performed a heterologous potency test according to the European Pharmacopoeia design using a field isolate from the A/IRN/05 lineage as the challenge virus. The estimated heterologous potency in this study was 2.0 (95% CI 0.4–6.0) PD50/dose, which is below the minimum potency recommended by the World Organisation for Animal Health (OIE). Furthermore, the cross-reactive antibody titres against the heterologous challenge virus were poor (≤log10 0.9), even in those cattle that had received the full dose of vaccine. The geometric mean r1-value was 0.2 (95% CI 0.03–0.8), similar to the potency ratio of 0.04 (95% CI 0.004–0.3). Vaccination decreased viraemia and virus excretion compared to the unvaccinated controls. Our results indicate that this A/G-VII vaccine does not provide sufficient protection against viruses belonging to the A/IRN/05 lineage and therefore the A/G-VII vaccine strain cannot replace the A/IRN/05 vaccine strain but could be considered an additional strain for use in vaccines and antigen banks.